The stock is listed on Nasdaq

Davis Polk advised the sole bookrunner in an SEC-registered direct offering by Atara Biotherapeutics, Inc. of 834,237 shares of common stock and pre-funded warrants to purchase 1,587,108 shares of its common stock, generating gross proceeds of approximately $16 million. Atara is listed on Nasdaq under the symbol “ATRA.”

Atara is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases.

The Davis Polk capital markets team included partner Emily Roberts and associates Rebecca Lei and Cole Davis. Partner Kara L. Mungovan and associate Kelsey Nelson provided tax advice. Partner David R. Bauer and associates Gabrielle Mazero and Elizabeth Pott provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

 

Copy link to share post